199 related articles for article (PubMed ID: 33445205)
1. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial.
Szeimies RM; Abels C; Kilic A; Reich H; Berger B; Schulze Zur Wiesche E; Schramm K; Litzka L; Heimstaedt-Muskett S; Masur C
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):823-830. PubMed ID: 36606529
[TBL] [Abstract][Full Text] [Related]
3. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
[TBL] [Abstract][Full Text] [Related]
5. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
[TBL] [Abstract][Full Text] [Related]
6. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
[TBL] [Abstract][Full Text] [Related]
7. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
[TBL] [Abstract][Full Text] [Related]
8. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study.
Masur C; Soeberdt M; Kilic A; Knie U; Abels C
Br J Dermatol; 2020 Jan; 182(1):229-231. PubMed ID: 31218668
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study.
Hyun MY; Son IP; Lee Y; Choi HG; Park KY; Li K; Kim BJ; Seo SJ; Kim MN; Hong CK
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):278-282. PubMed ID: 24909188
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
[TBL] [Abstract][Full Text] [Related]
13. [Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis].
Hund M; Sinkgraven R; Rzany B
J Dtsch Dermatol Ges; 2004 May; 2(5):343-9. PubMed ID: 16281522
[TBL] [Abstract][Full Text] [Related]
14. Hyperhidrosis Quality of Life Index (HidroQoL©): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial.
Gabes M; Jourdan C; Schramm K; Masur C; Abels C; Kamudoni P; Salek S; Apfelbacher C
Br J Dermatol; 2021 Mar; 184(3):473-481. PubMed ID: 32510573
[TBL] [Abstract][Full Text] [Related]
15. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
[TBL] [Abstract][Full Text] [Related]
16. Topical Botulinum Toxin Type A Liposomal Cream for Primary Axillary Hyperhidrosis: A Double-Blind, Randomized, Split-Site, Vehicle-Controlled Study.
Lueangarun S; Sermsilp C; Tempark T
Dermatol Surg; 2018 Aug; 44(8):1094-1101. PubMed ID: 29659406
[TBL] [Abstract][Full Text] [Related]
17. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
Nasir A; Bissonnette R; Maari C; DuBois J; Pene Dumitrescu T; Haddad J; Yamaguchi Y; Dalessandro M
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):145-151. PubMed ID: 29055158
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Axillary Bromhidrosis with Topical 2% Glycopyrronium Bromide Cream: A Prospective, Non-randomized, Open-label Study.
Gregoriou S; Markantoni V; Campanati A; Martina E; Offidani A; Kouris A; Platsidaki E; Bokotas H; Stratigos A; Rigopoulos D; Kontochristopoulos G
J Clin Aesthet Dermatol; 2021 Nov; 14(11):E61-E63. PubMed ID: 34980961
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact.
Lowe N; Naumann M; Eadie N
Medicine (Baltimore); 2023 Jul; 102(S1):e32764. PubMed ID: 37499084
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis.
Bloudek LM; Gillard KK; Nguyen VB; Klein SZ
J Med Econ; 2021; 24(1):29-37. PubMed ID: 33256494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
